Key result
Coadministration of atogepant and sumatriptan resulted in no clinically relevant pharmacokinetic interactions, though atogepant Cmax was reduced by 22% (GMR 0.78; 90% CI 0.69-0.89).
Why the study?
The study was conducted to evaluate potential pharmacokinetic interactions between atogepant and sumatriptan.
Does coadministration of atogepant and sumatriptan alter their pharmacokinetics in healthy adults?
RCT (n=30)
Open-label
Crossover
Does coadministration of atogepant and sumatriptan alter their pharmacokinetics in healthy adults?
Coadministration of atogepant and sumatriptan does not result in clinically relevant pharmacokinetic interactions, supporting their concurrent use.
Supports coadministration without dose adjustment; confirms no relevant pharmacokinetic interaction for this gepant-triptan pair.
Aim: To evaluate pharmacokinetic interactions of atogepant with sumatriptan, an open-label, randomized, crossover study was conducted. Patients & methods: Thirty healthy adults received atogepant 60 mg, sumatriptan 100 mg, or coadministered drugs. Primary end point was geometric mean ratios (GMRs) and 90% CIs of interventions for area under the plasma concentration–time curve from time 0 to t (AUC0-t) or infinity (AUC0-∞) and peak plasma concentration (Cmax). Results: Atogepant GMRs for AUC0-t and AUC0-∞ versus with sumatriptan were within 90% CI 0.80–1.25, indicating no interaction; atogepant Cmax was reduced by 22% (GMR: 0.78; 90% CI: 0.69–0.89) with sumatriptan. Sumatriptan GMRs for AUC0-t, AUC0-∞ and Cmax versus with atogepant were within 90% CI 0.80–1.25. Conclusion: Atogepant with sumatriptan had no clinically relevant pharmacokinetic interactions.
No takes yet. Share an insight, caveat, or question.
Boinpally et al. (2021) conducted an RCT in Healthy adults (n=30). Atogepant and sumatriptan coadministration vs. Atogepant alone and sumatriptan alone was evaluated on Geometric mean ratios (GMRs) and 90% CIs of interventions for AUC0-t, AUC0-∞, and Cmax (GMR 0.78, 95% CI 0.69-0.89). Coadministration of atogepant and sumatriptan resulted in no clinically relevant pharmacokinetic interactions, though atogepant Cmax was reduced by 22% (GMR 0.78; 90% CI 0.69-0.89).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: